Overview

This trial is active, not recruiting.

Conditions lung cancer, non small cell lung cancer
Treatments apricoxib, placebo
Phase phase 2
Sponsor Martin Edelman, MD
Collaborator Tragara Pharmaceuticals, Inc.
Start date November 2008
End date May 2012
Trial size 109 participants
Trial identifier NCT00771953, HP-00043076, UMGCC 0822

Summary

The primary objective is to determine the anti-tumor activity of the combination of apricoxib + either docetaxel (AP/DC) or pemetrexed (AP/PE) compared with placebo + either docetaxel (P/DC) or pemetrexed (P/PE) as measured by progression free survival in patients with Stage IIIb (pleural effusion)or Stage IV non-small cell lung cancer (NSCLC).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, investigator)
Primary purpose treatment
Arm
(Experimental)
Apricoxib 400mg once a day plus Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 every 21 days(Treating physician will determine chemotherapy drug as per his usual practice).
apricoxib
Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day + docetaxel or pemetrexed administered as an intravenous infusion on the first day of each 21 day cycle.
(Placebo Comparator)
Placebo once a day plus Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 every 21 days(Treating physician will determine chemotherapy drug as per his usual practice).
placebo
Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day + docetaxel or pemetrexed administered as an intravenous infusion on the first day of each 21 day cycle.

Primary Outcomes

Measure
Progression Free Survival
time frame: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Pathologically determined stage IV non-small cell lung cancer (NSCLC), including stage IIIb (pleural effusion) (histology or cytology acceptable). - Documented progression after 1 prior platinum-based chemotherapy. No more than one prior chemotherapy regimen is permitted. Patients may have also received erlotinib (before, after or concurrently with platinum based therapy). - Measurable disease by RECIST criteria - Age at least 18 years. - ECOG performance status of 0-2. - Required Laboratory Values (within 28 days before randomization) : - Hb ≥ 9.0gm/dL; transfusions permitted - ANC ≥ 1500/mm3 - Platelets ≥ 100,000/mm3 - INR ≤ 1.5 - Serum creatinine (Cr) within normal limits for laboratory OR Creatinine clearance greater than or equal to 45 ml/min. 24 hour measured CCr is also acceptable (calculated by the Cockcroft and Gault equation). - SGOT and SGPT < 2 X the ULN; if liver metastases are present then must be < 5 X the ULN - Bilirubin ≤ Institutional ULN - Albumin ≥ or equal to 2.5 mg/dl - May have been treated with anti-EGFR kinase therapy in addition to a platinum based therapy or concurrently with platinum therapy. - Provide written informed consent and HIPAA authorization and agree to abide by the study restrictions and return for the required assessments. - Women of child-bearing potential must have negative pregnancy test (serum B-HCG) with a sensitivity of at least 50 mIU/L within 7 days prior to the initiation of treatment and must have used effective contraception (recommended to be two reliable forms of contraception used simultaneously) or must have been sexually abstinent for at least 4 weeks prior to the negative pregnancy test through entry in the study. - Female patients and male patients with female partners of child-bearing potential must agree to sexual abstinence or to practice effective contraception (recommended to be two reliable forms of contraception used simultaneously). At least one non-hormonal method strongly recommended. Male patients with female sexual partners who are pregnant, or of childbearing potential must agree to use condoms during and for at least 1 month after the last dose of apricoxib. Exclusion Criteria: - Pregnant or breast feeding - Known hypersensitivity to apricoxib, docetaxel, other drugs formulated with polysorbate 80, pemetrexed, sulfonamides, aspirin, or other NSAIDs. - Radiation therapy within 2 weeks or chemotherapy within 3 weeks or non-cytotoxic investigational agents within 3 weeks of initiating study treatment or patients who have not recovered from adverse effects due to agents administered > 3 weeks prior to initiating study treatment. Screening for urinary PGE-M suppression may begin during this time period. - Evidence of New York Heart Association class III or greater cardiac disease. History of myocardial infarction, stroke, ventricular arrhythmia, or symptomatic conduction abnormality within 12 months. - Concurrent severe or uncontrolled medical disease that could compromise the safety of the patient or compromise the ability of the patient to complete the study. - Known HIV infection or AIDS. Testing not required. - Symptomatic central nervous system metastases; the patient must be stable after radiotherapy for ≥ 2 weeks. Patients must be off all steroid or antiseizure medications for this indication for ≥ 2 weeks. Patients with CNS metastases that are untreated are eligible if there is no evidence of midline shift, requirement for steroids or antiseizure medications or neurologic symptoms. - History of upper GI bleeding, ulceration, or perforation within the past 5 years. - Concurrent use of COX-2 inhibitors or other NSAIDs for 2 days prior to the first dose of study treatment and during study, including aspirin for 7 days prior to the first dose of study treatment and during study. - Previous COX-2 inhibitor therapy for this diagnosis.

Additional Information

Official title Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients
Principal investigator Martin J Edelman
Description Patients diagnosed with advanced non-small cell lung cancer that has not responded to platinum-based chemotherapy are eligible to particvpate in this study. Current standard treatments for this type of lung cancer are generally not effective in preventing the cancer from growing. The purpose of this study is to see if adding the drug apricoxib to standard chemotherapy is effective in treting NSCLC. Apricoxib is an investigational drug. Investigational means that it is not approved by the Food and Drug Administration (FDA). Laboratory studies suggest that apricoxib may be useful in the treatment of cancer . This is seen particularly when it is combined with chemotherapy drugs. However, this has not been proven in humans. Laboratory evidence indicates that apricoxib may benefit patients whose disease over-produces a substance called COX-2. COX-2 can be detected in the urine as a substance called PGE-M (prostaglandin E metabolite). It is thought that patients who have a PGE-M level in the urine that decreases by at least half after taking apricoxib may benefit more than patients whose urine PGE-M decreases by less than half after apricoxib. This study evaluated whether adding apricoxib to standard chemotherapy treatment will improve outcomes in patients with non-small cell lung cancer whose urine PGE-M decreases at least 50% after taking apricoxib. Apricoxib or placebo was added to either docetaxel or pemetrexed treatment.
Trial information was received from ClinicalTrials.gov and was last updated in May 2013.
Information provided to ClinicalTrials.gov by University of Maryland.